- Home
- TMQ vs AGEN Comparison
TMQ vs AGEN Comparison
Compare TMQ & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TMQ
- AGEN
- Stock Information
- Founded
- TMQ 2004
- AGEN 1994
- Country
- TMQ Canada
- AGEN United States
- Employees
- TMQ N/A
- AGEN N/A
- Industry
- TMQ Precious Metals
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TMQ Basic Materials
- AGEN Health Care
- Exchange
- TMQ Nasdaq
- AGEN Nasdaq
- Market Cap
- TMQ 83.6M
- AGEN 96.2M
- IPO Year
- TMQ N/A
- AGEN 2000
- Fundamental
- Price
- TMQ $0.96
- AGEN $2.84
- Analyst Decision
- TMQ
- AGEN Buy
- Analyst Count
- TMQ 0
- AGEN 3
- Target Price
- TMQ N/A
- AGEN $9.33
- AVG Volume (30 Days)
- TMQ 4.7M
- AGEN 478.9K
- Earning Date
- TMQ 10-08-2024
- AGEN 11-12-2024
- Dividend Yield
- TMQ N/A
- AGEN N/A
- EPS Growth
- TMQ N/A
- AGEN N/A
- EPS
- TMQ N/A
- AGEN N/A
- Revenue
- TMQ N/A
- AGEN $160,427,000.00
- Revenue This Year
- TMQ N/A
- AGEN N/A
- Revenue Next Year
- TMQ N/A
- AGEN $0.04
- P/E Ratio
- TMQ N/A
- AGEN N/A
- Revenue Growth
- TMQ N/A
- AGEN 59.00
- 52 Week Low
- TMQ $0.25
- AGEN $2.74
- 52 Week High
- TMQ $1.29
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- TMQ 70.55
- AGEN 20.16
- Support Level
- TMQ $0.91
- AGEN $2.98
- Resistance Level
- TMQ $1.29
- AGEN $4.42
- Average True Range (ATR)
- TMQ 0.11
- AGEN 0.26
- MACD
- TMQ 0.03
- AGEN -0.10
- Stochastic Oscillator
- TMQ 55.80
- AGEN 1.87
About TMQ Trilogy Metals Inc.
Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the United States. Its properties include the Arctic copper-zinc-lead-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).